Skip to main content

Table 1 Demographic and clinical data of patients with AD and controls

From: The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease

 

AD baseline

(n = 322)

AD 1-year follow-up

(n = 244)

AD 2-year follow-up

(n = 166)

Controls

(n = 88)

P value*

Male patients, n (%)

173 (53.7%)

128 (52.4%)

86 (51.8)

54 (61.4%)

0.19

Age (years)

80.4 (6.2)

80.3 (6.2)

79.6 (6.5)

77.0 (6.2)

<0.01

Education (years)

10.1 (4.4)

  

10.1 (5.1)

0.96

Disease duration (months)

52.4 (47.5)

  

BMI (kg/m2)

23.6 (3.4)

23.7 (3.3)

23.9 (3.3)

24.4 (3.2)

0.07

MMSE

18.1 (5.9)

16.7 (6.4)

16.5 (6.6)

27.2 (2.5)

<0.01

Delayed recall of 12-item memory test

1.1 (1.8)

    

Forward digit span

8.5 (3.2)

   

Backward digit span

3.9 (2.1)

   

Category verbal fluency

6.1 (3.0)

   

Modified Boston naming test

11.1 (3.1)

   

CDR, n (%)

 0.5

20 (6.2%)

10 (4.1%)

6 (3.6%)

  

 1

208 (64.6%)

129 (52.9%)

74 (44.6%)

 

 2

81 (25.2%)

81 (33.2%)

65 (39.2%)

 

 3

12 (3.7%)

23 (9.4%)

19 (11.4%)

 

NPI-agitation/aggression

7.0 (12.0)

7.9 (12.5)

6.9 (11.4)

 

NPI-mood

5.4 (9.4)

6.4 (9.9)

5.3 (8.6)

 

NPI-frontal

5.7 (10.1)

7.2 (11.4)

5.7 (8.4)

 

ApoE4 carrier, n (%)

135 (41.9%)

  

9 (10.2%)

< 0.01

Plasma clusterin level (μg/ml)

248.6 (37.9)

  

243.8 (35.9)

0.29

Aβ1–40 (pg/ml)

157.9 (50.7)

  

144.5 (36.9)

0.02

Aβ1–42 (pg/ml)

36.9 (20.8)

  

34.1 (9.1)

0.23

Ratio of Aβ1–42/Aβ1–40 (%)

23.7 (8.7)

  

24.4 (6.7)

0.32

  1. Values are shown as means and standard deviations unless otherwise indicated
  2. *Comparison between AD baseline and controls by Independent two sample t tests or Chi-square tests
  3. amyloid beta, AD Alzheimer’s disease, ApoE apolipoprotein E, BMI body mass index, CDR Clinical Dementia Rating, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory